Ionis Pharmaceuticals, Inc.
NASDAQ:IONSBiotechnology
+$1.22 today
- Market cap
- $4.56B
- Beta
- 0.37
- P/E (TTM)
- -37.5
- EPS (TTM)
- -$1.98
Volume 3.23M
Average 1.83M
IONS Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Ionis Pharmaceuticals, Inc.NASDAQ: IONS
Accumulated OCI · Q3 FY2026 · quarter ended Sep 2026
Accumulated OCI remains negative
Q3 FY2026 Accumulated OCI was -$39.82M, compared with -$25.98M a year earlier.
Context
- Accumulated OCI amounted to 1.4% of total assets at the end of Q3 FY2026, up 0.5 pp from a year earlier.
- Accumulated OCI grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -53.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (25.28M) USD
- Year-over-year change
- +17.9%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.28M) | +17.9% |
| FY2024 | 2024-12-31 | (30.81M) | +5.6% |
| FY2023 | 2023-12-31 | (32.65M) | +43.2% |
| FY2022 | 2022-12-31 | (57.48M) | -76.0% |
| FY2021 | 2021-12-31 | (32.67M) | — |
Accumulated OCI vs competitors
How IONS compares with its peers on the latest reported figures
- IONS's Sep 2026 Accumulated OCI of -$39.82M is the 7th highest of the 9 companies compared; the peer median is -$180.5K.
- Its year-over-year change of -53.3% is the 5th highest of 9, against a peer median of -70.5%.
- Accumulated OCI amounts to 1.4% of total assets for IONS, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10M | +3032.6% | — | 0.8% | |
| Jun 2026 | $6.02M | -18.2% | +29.9% | 0.2% | |
| Jun 2026 | -$7K | -800.0% | — | 0.0% | |
| Mar 2026 | -$121K | -455.9% | — | 0.0% | |
| Mar 2026 | -$240K | -122.7% | — | 0.0% | |
| Jun 2026 | -$32.14M | -7.3% | — | 0.6% | |
| Sep 2026 | -$39.82M | -53.3% | — | 1.4% | |
| Jun 2026 | -$127.7M | +46.4% | — | 0.4% | |
| Sep 2026 | -$4.01B | -11719.0% | — | 0.0% | |
| Peer median (excluding IONS) | -$180.5K | -70.5% | +29.9% | 0.1% | |
Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 869.19M | 276.47M | 399.27M | 242.08M | 372.26M |
| Short-term Investments | 1.26B | 1.72B | 1.93B | 2.06B | 2.31B |
| Net Receivables | 61.9M | 25.54M | 97.78M | 92.19M | 66M |
| Inventory | 24.81M | 22.03M | 7.44M | 12.51M | 10.05M |
| Other Current Assets | 125.17M | 157.72M | 205.43M | 217.93M | 247M |
| Total Current Assets | 2.35B | 2.2B | 2.64B | 2.62B | 2.99B |
| Property, Plant & Equipment (Net) | 196.04M | 255.84M | 242.94M | 256.11M | 362M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 29.01M | 0 | 0 | 0 | 0 |
| Long-term Investments | 32.32M | 40.37M | 42.99M | 41.02M | 52.21M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 9.27M | 34.97M | 62.29M | 86.26M | 119.39M |
| Total Non-current Assets | 266.64M | 331.18M | 348.22M | 383.39M | 533.2M |
| Total Assets | 2.61B | 2.53B | 2.99B | 3B | 3.52B |
| Account Payables | 11.9M | 17.92M | 26.03M | 42.96M | 28.08M |
| Short-term Debt | 3.53M | 7.54M | 53.16M | 9.28M | 453.15M |
| Tax Payables | 36K | 6.25M | 2.15M | 34K | 0 |
| Deferred Revenue | 97.71M | 90.58M | 151.13M | 78.99M | 73.76M |
| Other Current Liabilities | 38.81M | 49.18M | 67.73M | 69.61M | 107.63M |
| Total Current Liabilities | 240.55M | 311.56M | 448.09M | 309.32M | 781.57M |
| Long-term Debt | 1.23B | 1.18B | 1.23B | 1.25B | 1.9B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 351.88M | 287.77M | 241.18M | 156.5M | 92M |
| Other Non-current Liabilities | 0 | 0 | 513.74M | 542.21M | 0 |
| Total Non-current Liabilities | 1.6B | 1.65B | 2.16B | 2.11B | 2.25B |
| Total Liabilities | 1.84B | 1.96B | 2.6B | 2.42B | 3.03B |
| Common Stock | 141K | 142K | 144K | 158K | 163K |
| Retained Earnings | (1.16B) | (1.43B) | (1.8B) | (2.25B) | (2.63B) |
| Accumulated OCI | (32.67M) | (57.48M) | (32.65M) | (30.81M) | (25.28M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 771.74M | 572.89M | 386.69M | 588.35M | 489.09M |
| Total Debt | 1.25B | 1.37B | 1.45B | 1.42B | 2.61B |
| Net Debt | 381.86M | 1.09B | 1.05B | 1.17B | 2.24B |
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
Intrinsic Alpha fair value
Locked
Current Price
$27.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.